Fossett Lays Out Implications of Biotech Giant’s Decision to Cancel Clinical Trials of Human Embryonic Stem Cell Therapy

James Fossett, PhD

Albany N.Y. (February 21, 2012) -- James Fossett, Rockefeller College associate professor and director of the Rockefeller Institute’s health, Medicaid studies and bioethics research programs, writes on biotech giant Geron’s decision to cancel a clinical trial for a human embryonic stem cell (hESC) therapy, and the implications that decision is having in California and beyond. Read Fossett’s complete article.